PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10305964

A process for plan development under P.L. 93-641.

R Casterline
View original source ↗Export metadata ↓

Abstract

P.L. 93-641, the National Health Planning and Resources Development Act, specifies that health planning focus on health status as well as cost containment. It also specifies the integration of technical analysis with public involvement and political decision making. This paper suggests one planning process which can embody these difficult concepts. The process can be visualized as a series of four Decision Points at which the Governing Body of a Health Systems Agency takes action. Each Decision Point is supported by a staff Analysis which provides the decision makers with the best possible information about the area's health status and health system.

Explore related subjects

Decision MakingGoalsHealth PlanningHealth Systems AgenciesUnited StatesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Casterline. 1978. A process for plan development under P.L. 93-641.. https://pubmed.ncbi.nlm.nih.gov/10305964/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Genetic test evaluation: information needs of clinicians, policy makers, and the public.

Growing knowledge about gene-disease associations will lead to new opportunities for genetic testing. Many experts predict that genetic testing will become increasingly important as a guide to prevention, clinical management, and drug treatment based on genetic susceptibilities. As part of a Human Genetic Epidemiology workshop convened by the Centers for Disease Control and Prevention, a group of experts evaluated the evidence needed when considering the appropriate use of new genetic tests. Because new tests are likely to vary in their predictive value, their potential to direct prevention or treatment efforts, and their personal and social consequences, the task of determining appropriate use will require careful consideration of a variety of factors, including the analytic validity, clinical validity, clinical utility, and ethical, legal, and social implications of the test. Standardized formats are needed to summarize what is known and not known about new genetic tests with respect to each of these features. Following criteria for the objective assessment of test properties, reports should be structured to enable policy makers, clinicians, and the public to identify the available evidence, so that uncertainties can be taken into account when considering test use and planning future research.

Decision Making↗